Abstract
Paeonol, a naturally bioactive phenolic ingredient predominantly isolated from Paeonia suffruticosa, has recently garnered significant interest as an anti-tumor agent against diverse carcinomas including non-small cell lung cancer (NSCLC). However, the anti-tumor mechanism of paeonol in NSCLC remains unclear. Cell viability, caspase-3 activity, and apoptosis were evaluated using CCK-8 assay, Caspase-3 Colorimetric Assay Kit, and flow cytometry analysis, respectively. GSE186218 was downloaded from NCBI Gene Expression Omnibus (GEO). The common genes were screened using GEO2R and Draw Venn Diagram software. Expression of troponin C type 1 (TNNC1), scavenger receptor class A member 5 (SCARA5), phosphorylated protein kinase B (AKT) (p-AKT) and AKT was examined using GEPIA database, qRT-PCR and western blot analysis. Paeonol treatment concentration-dependently inhibited cell viability and increased caspase-3 activity and apoptotic rate in NSCLC cells. Only 5 overlapping genes including TNNC1 and SCARA5 were obtained among 232 upregulated genes in GSE186218, 200 underexpressed genes in TCGA-LUAD, and 200 underexpressed genes in TCGA-LUSC according to the Venn diagram software. TNNC1 and SCARA5, two known tumor suppressors, were significantly downregulated in LUAD and LUSC tissues and NSCLC cells. Paeonol dose-dependently upregulated TNNC1 and SCARA5 expression in NSCLC cells. Paeonol suppressed the AKT pathway by upregulating TNNC1 and SCARA5 expression. AKT inhibitor attenuated the effects of TNNC1 or SCARA5 knockdown on the anti-tumor activity of paeonol. In conclusion, paeonol exhibited anti-cancer activity in NSCLC cells through inactivating the AKT pathway by upregulating TNNC1 or SCARA5.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The data and materials of this study are available from the corresponding author upon reasonable request.
References
Alharbi KS, Shaikh MAJ, Almalki WH, Kazmi I, Al-Abbasi FA, Alzarea SI et al (2022) PI3K/Akt/mTOR pathways inhibitors with potential prospects in non-small-cell lung cancer. J Environ Pathol Toxicol Oncol 41(4):85–102. https://doi.org/10.1615/JEnvironPatholToxicolOncol.2022042281
Alzahrani AS (2019) PI3K/Akt/mTOR inhibitors in cancer: at the bench and bedside. Semin Cancer Biol 59:125–132. https://doi.org/10.1016/j.semcancer.2019.07.009
Cai J, Chen Y, Wang K, Li Y, Wu J, Yu H et al (2023) Decoding the key compounds and mechanism of Shashen Maidong decoction in the treatment of lung cancer. BMC Complement Med Ther 23(1):158. https://doi.org/10.1186/s12906-023-03985-y
Chanvorachote P, Chamni S, Ninsontia C, Phiboonchaiyanan PP (2016) Potential anti-metastasis natural compounds for lung cancer. Anticancer Res 36(11):5707–5717. https://doi.org/10.21873/anticanres.11154
Chen C, Jia F, Hou Z, Ruan S, Lu Q (2017) Delivery of paeonol by nanoparticles enhances its in vitro and in vivo antitumor effects. Int J Nanomedicine 12:6605–6616. https://doi.org/10.2147/ijn.s143938
Chen X, Xu Z, Lu M, Ding W, Zhong J, Deng S et al (2023) Paeonol inhibits melanoma growth by targeting PD1 through upregulation of miR-139-5p. Biochem Biophys Res Commun 656:86–96. https://doi.org/10.1016/j.bbrc.2023.03.005
Choy KW, Lau YS, Murugan D, Mustafa MR (2017) Chronic treatment with paeonol improves endothelial function in mice through inhibition of endoplasmic reticulum stress-mediated oxidative stress. PLoS ONE 12(5):e0178365. https://doi.org/10.1371/journal.pone.0178365
Duma N, Santana-Davila R, Molina JR (2019) Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc 94(8):1623–1640. https://doi.org/10.1016/j.mayocp.2019.01.013
Fang C, Zhang X, Li C, Liu F, Liu H (2022) Troponin C-1 activated by E2F1 accelerates gastric cancer progression via regulating TGF-β/Smad signaling. Dig Dis Sci 67(9):4444–4457. https://doi.org/10.1007/s10620-021-07287-6
Fang Y, Wu F, Shang G, Yin C (2023) SCARA5 in bone marrow stromal cell-derived exosomes inhibits colorectal cancer progression by inactivating the PI3K/Akt pathway. Genomics 115(4):110636. https://doi.org/10.1016/j.ygeno.2023.110636
Gai C, Yu M, Li Z, Wang Y, Ding D, Zheng J et al (2020) Acetaminophen sensitizing erastin-induced ferroptosis via modulation of Nrf2/heme oxygenase-1 signaling pathway in non-small-cell lung cancer. J Cell Physiol 235(4):3329–3339. https://doi.org/10.1002/jcp.29221
Herbst RS, Morgensztern D, Boshoff C (2018) The biology and management of non-small cell lung cancer. Nature 553(7689):446–454. https://doi.org/10.1038/nature25183
Hong M, Shi H, Wang N, Tan HY, Wang Q, Feng Y (2019) Dual effects of Chinese herbal medicines on angiogenesis in cancer and ischemic stroke treatments: role of HIF-1 network. Front Pharmacol 10:696. https://doi.org/10.3389/fphar.2019.00696
Huang J, Lv C, Zhao B, Ji Z, Gao Z (2023) SCARA5 inhibits oral squamous cell carcinoma via inactivating the STAT3 and PI3K/AKT signaling pathways. Open Med 18(1):20230627. https://doi.org/10.1515/med-2023-0627
Jiang Y, Oliver P, Davies KE, Platt N (2006) Identification and characterization of murine SCARA5, a novel class a scavenger receptor that is expressed by populations of epithelial cells. J Biol Chem 281(17):11834–11845. https://doi.org/10.1074/jbc.M507599200
Jumai K, Zhang T, Qiao B, Ainiwaer J, Zhang H, Hou Z et al (2022) Highly expressing SCARA5 promotes proliferation and migration of esophageal squamous cell carcinoma. J Immunol Res 2022:2555647. https://doi.org/10.1155/2022/2555647
Kim S, Kim J (2020) Characterization of TNNC1 as a novel tumor suppressor of lung adenocarcinoma. Mol Cells 43(7):619–631. https://doi.org/10.14348/molcells.2020.0075
Lee H, Lee G, Kim H, Bae H (2013) Paeonol, a major compound of moutan cortex, attenuates cisplatin-induced nephrotoxicity in mice. Evid Based Complement Alternat Med 2013(310989). https://doi.org/10.1155/2013/310989
Li MX, Hwang PM (2015) Structure and function of cardiac troponin C (TNNC1): implications for heart failure, cardiomyopathies, and troponin modulating drugs. Gene 571(2):153–166. https://doi.org/10.1016/j.gene.2015.07.074
Li N, Fan LL, Sun GP, Wan XA, Wang ZG, Wu Q et al (2010) Paeonol inhibits tumor growth in gastric cancer in vitro and in vivo. World J Gastroenterol 16(35):4483–4490. https://doi.org/10.3748/wjg.v16.i35.4483
Li Y, Peng F, Tan X, Wang J, Xu Y (2021) Tumor suppressive effect of scavenger receptor class A member 5 overexpression in colorectal cancer by regulating PI3K/AKT/mTOR pathway. Genes Genomics 43(10):1189–1198. https://doi.org/10.1007/s13258-021-01139-3
Liu J, Hu G, Chen D, Gong AY, Soori GS, Dobleman TJ et al (2013) Suppression of SCARA5 by Snail1 is essential for EMT-associated cell migration of A549 cells. Oncogenesis 2(9):e73. https://doi.org/10.1038/oncsis.2013.37
Liu LH, Shi RJ, Chen ZC (2020) Paeonol exerts anti–tumor activity against colorectal cancer cells by inducing G0/G1 phase arrest and cell apoptosis via inhibiting the Wnt/β–catenin signaling pathway. Int J Mol Med 46(2):675–684. https://doi.org/10.3892/ijmm.2020.4629
Lu XS, Huang ML, Chen LB, Liu SC, Huang ZX, Liu SM (2023) SCARA5 as a downstream factor of PCAT29, inhibits proliferation, migration, and invasion of bladder cancer. Genomics 115(5):110667. https://doi.org/10.1016/j.ygeno.2023.110667
Ma F, Wang Z, Qiang Y, Xu L, Ding P, Wang Y, Ma X (2020) LukS-PV inhibits hepatocellular carcinoma cells migration via the TNNC1/PI3K/AKT axis. Onco Targets Ther 13:10221–10230. https://doi.org/10.2147/OTT.S278540
Marquard FE, Jücker M (2020) PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer. Biochem Pharmacol 172:113729. https://doi.org/10.1016/j.bcp.2019.113729
Morsy MA, Abdel-Aziz AM, Abdel-Hafez SMN, Venugopala KN, Nair AB, Abdel-Gaber SA (2020) The possible contribution of P-glycoprotein in the protective effect of paeonol against methotrexate-induced testicular injury in rats. Pharmaceuticals (Basel) 13(9):223. https://doi.org/10.3390/ph13090223
Osarogiagbon RU, Veronesi G, Fang W, Ekman S, Suda K, Aerts JG et al (2019) Early-stage NSCLC: advances in thoracic oncology 2018. J Thorac Oncol 14(6):968–978. https://doi.org/10.1016/j.jtho.2019.02.029
Peng Q, Liu Y, Kong X, Xian J, Ye L, Yang L et al (2021) The novel methylation biomarker SCARA5 sensitizes cancer cells to DNA damage chemotherapy drugs in NSCLC. Front Oncol 11:666589. https://doi.org/10.3389/fonc.2021.666589
Siegel RL, Miller KD (2021) Cancer statistics, 2021. CA Cancer J Clin 71(1):7–33. https://doi.org/10.3322/caac.21654
Song YJ, Gao XH, Hong YQ, Wang LX (2018) Direct bilirubin levels are prognostic in non-small cell lung cancer. Oncotarget 9(1):892–900. https://doi.org/10.18632/oncotarget.23184
Song M, Bode AM, Dong Z, Lee MH (2019) AKT as a therapeutic target for cancer. Cancer Res 79(6):1019–1031. https://doi.org/10.1158/0008-5472.CAN-18-2738
Sung H, Ferlay J, Siegel RL (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660
Tan AC (2020) Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC). Thorac Cancer 11(3):511–518. https://doi.org/10.1111/1759-7714.13328
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z (2017) GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 45(W1):W98–w102. https://doi.org/10.1093/nar/gkx247
Tash JS, Means AR (1982) Regulation of protein phosphorylation and motility of sperm by cyclic adenosine monophosphate and calcium. Biol Reprod 26(4):745–763. https://doi.org/10.1095/biolreprod26.4.745
Toro-Domínguez D, Martorell-Marugán J, López-Domínguez R, García-Moreno A, González-Rumayor V, Alarcón-Riquelme ME et al (2019) ImaGEO: integrative gene expression meta-analysis from GEO database. Bioinformatics 35(5):880–882. https://doi.org/10.1093/bioinformatics/bty721
Wang J, Wang S, Chen L, Tan J (2021) SCARA5 suppresses the proliferation and migration, and promotes the apoptosis of human retinoblastoma cells by inhibiting the PI3K/AKT pathway. Mol Med Rep 23(3):202. https://doi.org/10.3892/mmr.2021.11841
Wu J, Xue X, Zhang B, Jiang W, Cao H, Wang R, Sun D, Guo R (2016) The protective effects of paeonol against epirubicin-induced hepatotoxicity in 4T1-tumor bearing mice via inhibition of the PI3K/Akt/NF-kB pathway. Chem Biol Interact 244:1–8. https://doi.org/10.1016/j.cbi.2015.11.025
Wu C, Yang J, Li R, Lin X, Wu J, Wu J (2021) LncRNA WT1-AS/miR-494-3p regulates cell proliferation, apoptosis, migration and invasion via PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer. Onco Targets Ther 14:891–904. https://doi.org/10.2147/ott.s278233
Xing P, Mu Y (2018) Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer. Thorac Cancer 9(7):805–813. https://doi.org/10.1111/1759-7714.12650
Yang SR, Schultheis AM, Yu H, Mandelker D, Ladanyi M, Büttner R (2022) Precision medicine in non-small cell lung cancer: current applications and future directions. Semin Cancer Biol 84:184–198. https://doi.org/10.1016/j.semcancer.2020.07.009
Ye X, Xie G, Liu Z, Tang J, Cui M, Wang C et al (2020) TNNC1 reduced gemcitabine sensitivity of nonsmall-cell lung cancer by increasing autophagy. Med Sci Monit 26:e922703. https://doi.org/10.12659/msm.922703
Yin JH, Elumalai P, Kim SY, Zhang SZ, Shin S, Lee M et al (2021) TNNC1 knockout reverses metastatic potential of ovarian cancer cells by inactivating epithelial-mesenchymal transition and suppressing F-actin polymerization. Biochem Biophys Res Commun 547:44–51. https://doi.org/10.1016/j.bbrc.2021.02.021
You K, Su F, Liu L, Lv X, Zhang J, Zhang Y, Liu B (2017) SCARA5 plays a critical role in the progression and metastasis of breast cancer by inactivating the ERK1/2, STAT3, and AKT signaling pathways. Mol Cell Biochem 435(1–2):47–58. https://doi.org/10.1007/s11010-017-3055-4
Zhang L, Li DC, Liu LF (2019) Paeonol: pharmacological effects and mechanisms of action. Int Immunopharmacol 72:413–421. https://doi.org/10.1016/j.intimp.2019.04.033
Zhang L, Chen WX, Li LL, Cao YZ, Geng YD, Feng XJ et al (2020) Paeonol suppresses proliferation and motility of non-small-cell lung cancer cells by disrupting STAT3/NF-κB signaling. Front Pharmacol 11:572616. https://doi.org/10.3389/fphar.2020.572616
Funding
This work was supported by the Science and Technology Plan Project of Jinzhou (JZ2023B040).
Author information
Authors and Affiliations
Contributions
Chongnan Zhang, Jing Zhang, and Kai Guo contributed to investigation, supervision, data collection and analysis, and article writing. All authors reviewed the manuscript. The authors declare that all data were generated in-house and that no paper mill was used. This is not the case in your accepted article.
Corresponding author
Ethics declarations
Ethics approval
Not applicable.
Competing interests
The authors have no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Zhang, C., Zhang, J. & Guo, K. Paeonol upregulates expression of tumor suppressors TNNC1 and SCARA5, exerting anti-tumor activity in non-small cell lung cancer cells. Naunyn-Schmiedeberg's Arch Pharmacol 397, 5241–5251 (2024). https://doi.org/10.1007/s00210-024-02963-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-024-02963-6